

## INTERNATIONAL SEARCH REPORT

Inter. No. 10/519035  
PCT/EP 03/50277

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 G06F19/00 C12Q1/70 C12N9/50

22 DEC 2004

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, SEQUENCE SEARCH

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SCHINAZI ET AL.: "Mutations in retroviral genes associated with drug resistance: 2000-2001 update" INTERNATIONAL ANTIVIRAL NEWS, vol. 8, no. 5, 2000, pages 65-91, XP009018670 the whole document ---	1-20
X	DATABASE NCBI 15 November 2000 (2000-11-15) VERGNE ET AL.: "POL precursor" Database accession no. CAC03089 XP002258544 mutation 41S the whole document ---	15-20 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

21 October 2003

Date of mailing of the international search report

10/11/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patenttaan 2  
NL-2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

van Heusden, M

## INTERNATIONAL SEARCH REPORT

Interr. No.  
PCT/EP 03/50277

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	VERGNE LAURENCE ET AL: "Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: Evidence of many minor drug resistance mutations in treatment-naive patients" JOURNAL OF CLINICAL MICROBIOLOGY, vol. 38, no. 11, November 2001 (2001-11), pages 3919-3925, XP002258541 ISSN: 0095-1137 mutation 41K and mutation 70E (group 0) page 3923, left-hand column; figure 2 ---	15-20
X	DATABASE NCBI 12 June 2002 (2002-06-12) SCHMIDT ET AL.: "pol protein (HIV-1)" Database accession no. AAK32676 XP002258545 mutation 41T the whole document ---	15-20
X	DATABASE NCBI 23 May 2002 (2002-05-23) ESHLEMAN ET AL.: "HIV1 isolate 420111k042398 from USA pol protein (pol) gene" Database accession no. AF357746 XP002258546 mutation 41I the whole document ---	15-20
P, X	DATABASE SWISSPROT 1 June 2003 (2003-06-01) WATKINS ET AL.: "Protease HIV1" Database accession no. Q7ZCQ9 XP002258547 mutation 41I the whole document ---	15-20
X	RUSCONI STEFANO ET AL: "Susceptibility to PNU-140690 (tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors" ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 44, no. 5, May 2000 (2000-05), pages 1328-1332, XP002258542 ISSN: 0066-4804 mutation 41K page 1330, left-hand column, paragraph 3 ---	5-8, 11-20

-/-

## INTERNATIONAL SEARCH REPORT

Internation No  
PCT/EP 03/50277

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE NCBI13 April 2001 (2001-04-13) SHAFER ET AL.: "HIV-1 isolate PCCPROT48 from USA, protease (pol) gene" Database accession no. AF085133 XP002258548 mutation 41K the whole document ---	15-20
X	DATABASE SWISSPROT 1 July 1997 (1997-07-01) CONDRA ET AL.: "HIV-1 protease" Database accession no. O10176 XP002258549 Mutation 41K the whole document ---	15-20
X	CONDRA J ET AL: "Genetic correlation of in vivo viral isolates to indinavir, a human immunodeficiency type 1 protease inhibitor" JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 70, no. 12, December 1996 (1996-12), pages 8270-76, XP002150116 ISSN: 0022-538X mutation 41K table 1 ---	5-8, 11-20
X	HERTOGS ET AL: "A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs" ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US, vol. 42, no. 2, February 1998 (1998-02), pages 269-276, XP002137814 ISSN: 0066-4804 mutation 41K table 6 ---	1-20
		-/-

## INTERNATIONAL SEARCH REPORT

Intern	lication No
PCT/EP 03/50277	

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	VASUDEVACHARI M B ET AL: "EMERGENCE OF PROTEASE INHIBITOR RESISTANCE MUTATIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 ISOLATES FROM PATIENTS AND RAPID SCREENING PROCEDURE FOR THEIR DETECTION" ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US, vol. 40, no. 11, November 1996 (1996-11), pages 2535-2541, XP000901688 ISSN: 0066-4804 mutation 41K figure 4 ---	15-20
X	DATABASE NCBI12 June 2002 (2002-06-12) SCHMIDT ET AL.: "HIV-1 isolate 992286 from Germany pol protein (pol) gene" Database accession no. AF347471 XP002258550 mutation 41Q the whole document ---	15-20
X	DATABASE NCBI30 August 2000 (2000-08-30) ABREMSKI ET AL.: "pol protein HIV-1" Database accession no. AAG03320 XP002258551 mutation 41G the whole document ---	15-20
X	DATABASE NCBI16 August 2001 (2001-08-16) GONZALES ET AL.: "pol polyprotein (HIV-1)" Database accession no. AAK35843 XP002258552 mutation 70E the whole document ---	15-20
X	DATABASE NCBI3 February 2000 (2000-02-03) MARTINEZ ET AL.: "protease (HIV-1)" Database accession no. AAF29689 XP002258553 mutation 70E the whole document ---	15-20
X	IBÁÑEZ A ET AL: "Human immunodeficiency virus type 1 population bottleneck during indinavir therapy causes a genetic drift in the env quasispecies." THE JOURNAL OF GENERAL VIROLOGY. ENGLAND JAN 2000, vol. 81, no. Pt 1, January 2000 (2000-01), pages 85-95, XP002258543 ISSN: 0022-1317 mutations 41K and 70E figure 2A ---	1-20
		-/-

## INTERNATIONAL SEARCH REPORT

Int'l Application No  
PCT/EP 03/50277

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 01 79540 A (DEHERTOGH PASCALE ALFONS ROSA ;HERTOGS KURT (BE); VIRCO NV (BE); M) 25 October 2001 (2001-10-25) the whole document ---	1-20
A	WO 02 22076 A (VIROLOGIC INC) 21 March 2002 (2002-03-21) the whole document ---	1-20
A	WO 99 67428 A (INNOGENETICS NV ;STUYVER LIEVEN (BE)) 29 December 1999 (1999-12-29) the whole document -----	1-20

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP 03/50277

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
  
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1,3,5,7,9,11,13,15,17,19 (partially)

A computer system correlating the presence of the mutation 41S in HIV-1 protease with a change in susceptibility to a protease inhibitor, methods of evaluating the effectiveness of a protease inhibitor against said protease mutant and of identifying drugs effective against said protease mutant, a vector comprising an HIV sequence having said mutation, an isolated HIV protease having said mutation and an oligonucleotide comprising an HIV protease sequence having said mutation.

2. Claims: 1-20 (partially)

A computer system correlating the presence of the mutation 41T in HIV-1 protease with a change in susceptibility to a protease inhibitor, methods of evaluating the effectiveness of a protease inhibitor against said protease mutant and of identifying drugs effective against said protease mutant, a vector comprising an HIV sequence having said mutation, an isolated HIV protease having said mutation and an oligonucleotide comprising an HIV protease sequence having said mutation.

3. Claims: 1-20 (partially)

A computer system correlating the presence of the mutation 41I in HIV-1 protease with a change in susceptibility to a protease inhibitor, methods of evaluating the effectiveness of a protease inhibitor against said protease mutant and of identifying drugs effective against said protease mutant, a vector comprising an HIV sequence having said mutation, an isolated HIV protease having said mutation and an oligonucleotide comprising an HIV protease sequence having said mutation.

4. Claims: 1-20 (partially)

A computer system correlating the presence of the mutation 41K in HIV-1 protease with a change in susceptibility to a protease inhibitor, methods of evaluating the effectiveness of a protease inhibitor against said protease mutant and of identifying drugs effective against said protease mutant, a vector comprising an HIV sequence having said mutation, an isolated HIV protease having said mutation and an oligonucleotide comprising an HIV protease sequence having said mutation.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

5. Claims: 1-20 (partially)

A computer system correlating the presence of the mutation 41G in HIV-1 protease with a change in susceptibility to a protease inhibitor, methods of evaluating the effectiveness of a protease inhibitor against said protease mutant and of identifying drugs effective against said protease mutant, a vector comprising an HIV sequence having said mutation, an isolated HIV protease having said mutation and an oligonucleotide comprising an HIV protease sequence having said mutation.

6. Claims: 1-20 (partially)

A computer system correlating the presence of the mutation 70E in HIV-1 protease with a change in susceptibility to a protease inhibitor, methods of evaluating the effectiveness of a protease inhibitor against said protease mutant and of identifying drugs effective against said protease mutant, a vector comprising an HIV sequence having said mutation, an isolated HIV protease having said mutation and an oligonucleotide comprising an HIV protease sequence having said mutation.

## INTERNATIONAL SEARCH REPORT

Inter	Application No
PCT/EP 03/50277	

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 0179540	A	25-10-2001	AU CA WO EP US	6022401 A 2406140 A1 0179540 A2 1332231 A2 2002091664 A1		30-10-2001 25-10-2001 25-10-2001 06-08-2003 11-07-2002
WO 0222076	A	21-03-2002	AU CA EP WO US	9092301 A 2422815 A1 1322779 A2 0222076 A2 2002064838 A1		26-03-2002 21-03-2002 02-07-2003 21-03-2002 30-05-2002
WO 9967428	A	29-12-1999	AU AU BR CA WO EP JP	762811 B2 4900199 A 9911395 A 2330234 A1 9967428 A2 1090147 A2 2002518065 T		03-07-2003 10-01-2000 06-11-2001 29-12-1999 29-12-1999 11-04-2001 25-06-2002